94 related articles for article (PubMed ID: 21228127)
1. A West Nile virus mutant with increased resistance to acid-induced inactivation.
Martín-Acebes MA; Saiz JC
J Gen Virol; 2011 Apr; 92(Pt 4):831-40. PubMed ID: 21228127
[TBL] [Abstract][Full Text] [Related]
2. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice.
Liu WJ; Wang XJ; Clark DC; Lobigs M; Hall RA; Khromykh AA
J Virol; 2006 Mar; 80(5):2396-404. PubMed ID: 16474146
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the endocytic pathway mediating the infectious entry of mosquito-borne flavivirus West Nile into Aedes albopictus mosquito (C6/36) cells.
Chu JJ; Leong PW; Ng ML
Virology; 2006 Jun; 349(2):463-75. PubMed ID: 16490225
[TBL] [Abstract][Full Text] [Related]
4. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
[TBL] [Abstract][Full Text] [Related]
5. Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses.
Lee E; Hall RA; Lobigs M
J Virol; 2004 Aug; 78(15):8271-80. PubMed ID: 15254199
[TBL] [Abstract][Full Text] [Related]
6. West Nile virus is neutralized by HOCl-modified human serum albumin that binds to domain III of the viral envelope protein E.
Vossmann M; Kirst M; Ludolfs D; Schreiber M
Virology; 2008 Apr; 373(2):322-8. PubMed ID: 18191981
[TBL] [Abstract][Full Text] [Related]
7. In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses.
Kampmann T; Yennamalli R; Campbell P; Stoermer MJ; Fairlie DP; Kobe B; Young PR
Antiviral Res; 2009 Dec; 84(3):234-41. PubMed ID: 19781577
[TBL] [Abstract][Full Text] [Related]
8. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
[TBL] [Abstract][Full Text] [Related]
9. A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus.
Maier CC; Delagrave S; Zhang ZX; Brown N; Monath TP; Pugachev KV; Guirakhoo F
Virology; 2007 Jun; 362(2):468-74. PubMed ID: 17303204
[TBL] [Abstract][Full Text] [Related]
10. Obatoclax Inhibits Alphavirus Membrane Fusion by Neutralizing the Acidic Environment of Endocytic Compartments.
Varghese FS; Rausalu K; Hakanen M; Saul S; Kümmerer BM; Susi P; Merits A; Ahola T
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993855
[TBL] [Abstract][Full Text] [Related]
11. Antiviral peptides targeting the west nile virus envelope protein.
Bai F; Town T; Pradhan D; Cox J; Ashish ; Ledizet M; Anderson JF; Flavell RA; Krueger JK; Koski RA; Fikrig E
J Virol; 2007 Feb; 81(4):2047-55. PubMed ID: 17151121
[TBL] [Abstract][Full Text] [Related]
12. Sequential conformational rearrangements in flavivirus membrane fusion.
Chao LH; Klein DE; Schmidt AG; Peña JM; Harrison SC
Elife; 2014 Dec; 3():e04389. PubMed ID: 25479384
[TBL] [Abstract][Full Text] [Related]
13. A single amino acid substitution in the core protein of West Nile virus increases resistance to acidotropic compounds.
Martín-Acebes MA; Blázquez AB; de Oya NJ; Escribano-Romero E; Shi PY; Saiz JC
PLoS One; 2013; 8(7):e69479. PubMed ID: 23874963
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
Fredericksen BL; Whitt MA
Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system.
Widman DG; Ishikawa T; Fayzulin R; Bourne N; Mason PW
Vaccine; 2008 May; 26(22):2762-71. PubMed ID: 18423946
[TBL] [Abstract][Full Text] [Related]
16. Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations.
Yu L; Robert Putnak J; Pletnev AG; Markoff L
Vaccine; 2008 Nov; 26(47):5981-8. PubMed ID: 18805457
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity.
Roberson JA; Crill WD; Chang GJ
J Clin Microbiol; 2007 Oct; 45(10):3167-74. PubMed ID: 17715375
[TBL] [Abstract][Full Text] [Related]
18. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E.
Allison SL; Schalich J; Stiasny K; Mandl CW; Heinz FX
J Virol; 2001 May; 75(9):4268-75. PubMed ID: 11287576
[TBL] [Abstract][Full Text] [Related]
19. Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus.
Ledizet M; Kar K; Foellmer HG; Bonafé N; Anthony KG; Gould LH; Bushmich SL; Fikrig E; Koski RA
J Infect Dis; 2007 Dec; 196(12):1741-8. PubMed ID: 18190253
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of immunoglobulin M (IgM) capture enzyme-linked immunosorbent assay using virus-like particles or virus-infected mouse brain antigens to detect IgM antibody in sera from patients with evident flaviviral infections.
Holmes DA; Purdy DE; Chao DY; Noga AJ; Chang GJ
J Clin Microbiol; 2005 Jul; 43(7):3227-36. PubMed ID: 16000440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
